Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 61, Issue 7, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00451-17
Keywords
beta-lactamase inhibitor; avibactam; KPC-2; carbapenemase; ceftazidime
Categories
Ask authors/readers for more resources
The ceftazidime-avibactam antibiotic combination was recently shown to be at risk for the emergence of resistance under treatment. To gain insight into the underlying mechanism, we have analyzed the catalytic properties of a Klebsiella pneumoniae carbapenemase type 2 (KPC-2) beta-lactamase harboring the (DY)-Y-179 substitution. We show that impaired inhibition by avibactam combined with significant residual activity for ceftazidime hydrolysis accounts for the resistance. In contrast, the (DY)-Y-179 substitution abolished the hydrolysis of aztreonam and imipenem, indicating that these drugs might provide therapeutic alternatives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available